We have previously shown that IL-30 boosts cancer cell expression of CCL4, CSF-2, CSF-3, CXCL1, CXCL2 and PTGS2, which along with IL-1β, IL-6 and TNFα, promotes MDC accumulation and immunosuppressive activity [8, 31], whereas IL-30 silencing in PC-SLCs, reduces the tumor infiltration of MDCs, depletes the vascular supply and prevents or delays PC onset and progression [8]. The gene discussed is IL6; the disease is cancer.